Proniras key facts
as of Oct 2026- Operator of a clinical-stage biotechnology company intended for the development of novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system (CNS)…
- Proniras is valued at approximately $17.5M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $11.2M across 2 recorded rounds; the latest was Early Stage VC ($6.9M) in Dec 2023.
- Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Johnson & Johnson JJDC, WRF Capital, Eli Lilly and Company Foundation — 9 tracked in total.
- Proniras has filed 4 Form Ds with the SEC since 2017, most recently Jan 2025 ($6.9M sold to 10 investors).
- Status: Privately Held (backing).
Valued at $17.5M at its later-stage round, Jan 2025. Nothing has traded since.
- ·Watch Proniras: the Monday email on marks, rounds and moves
Proniras funding rounds
2 roundsProniras valuation
Proniras was valued at $17.5 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Proniras raised?
Proniras has raised $11.2 million across 2 recorded rounds since 2017. The largest was a $6.9 million early-stage round in Dec 2023.
Proniras has filed 4 Form Ds with the SEC since 2017, most recently in Jan 2025 ($6.9 million sold to 10 investors).
Proniras investors
9 investors are on record for Proniras, including Alexandria Venture Investments, ARCH Venture Partners, Johnson & Johnson JJDC and WRF Capital. The early-stage round in Dec 2023 drew 10 investors.
About Proniras
Operator of a clinical-stage biotechnology company intended for the development of novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system (CNS) disorders. The company offers parenteral medical countermeasure (MCM) therapies aimed at the development of drugs for the treatment of neurological conditions with high unmet medical needs, enabling medical researchers to antagonize glutamate signaling in the central nervous system.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2017
- Employees
- 4
- Website
- proniras.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.